CymaBay Therapeutics, Inc.

CymaBay did not report revenue on this call. Net loss for the third quarter of 2023 was $33.9 million, or $0.32 per share, versus $24.5 million, or $0.28 per share, in the prior-year quarter. R&D expense was $20.0 million versus $15.5 million a year ago, and G&A expense was $12.2 million versus $5.9 million a year ago. Cash, cash equivalents and investments totaled $438.8 million as of September 30, 2023, aided by an upsized public equity offering that generated $242.8 million in net proceeds. Management said this cash position is sufficient to fund operating expenses into the first half of 2026. Looking ahead, the company expects R&D and G&A spending to increase, with commercialization efforts accelerating in Q4 and beyond as it prepares for a potential seladelpar launch.

Sujal Shah framed the quarter as a major turning point, emphasizing that RESPONSE established seladelpar as a potentially differentiated treatment for PBC with both liver chemistry improvement and itch reduction. He highlighted the revised FDA breakthrough designation, active engagement with FDA, MHRA and EMA, and the company’s push toward high-quality regulatory filings as quickly as possible. He also underscored broader PBC commitments through IDEAL and AFFIRM, plus early commercial build-out and supply chain preparation.

Harish Shantharam said the quarter was successful operationally and financially, pointing to the $438.8 million cash, cash equivalents and investments balance at quarter-end and the $242.8 million net proceeds from the September equity offering. He noted that the company believes its cash and investments are enough to fund operating expenses into the first half of 2026. He also said Q3 R&D rose to $20.0 million from $15.5 million and G&A rose to $12.2 million from $5.9 million, driven by IDEAL/AFFIRM clinical activity and commercial/medical affairs build-out; he expects both expense lines to increase further.

Analysts focused on NDA timing, priority review, and what additional data would be shown at The Liver Meeting to support a best-in-class profile; management said a filing in roughly four to six months would not be unreasonable and that it intends to request rolling submission and priority review. Questions also centered on Europe, including whether regulators are aligned on outcomes data and whether the U.S. breakthrough designation implies a similarly differentiated EU label; management said U.S. and EU regulators are broadly aligned on the need for outcomes evidence, but noted that breakthrough therapy designation is FDA-specific and it is still early to conclude how ex-U.S. regulators will view the package. In AFFIRM, management addressed feasibility and powering by saying the design reflects long-standing FDA discussions, a 2:1 randomization, a three-year fixed duration, and a compensated cirrhosis population chosen partly because there are limited options and event rates support the study design. Analysts also asked about commercial strategy and competitive differentiation versus elafibranor; management emphasized that seladelpar’s itch data, ALP normalization, and broader anti-cholestatic/anti-inflammatory profile remain central, and said it expects a U.S. sales force of about 50 to 60 reps covering 5,000 to 7,000 GI/hepatology targets.